Back to results
US 5,585,362 AGranted
Adenovirus vectors for gene therapy
AssigneeThe Regents of the University of Michigan
InventorsJames M. Wilson, John Engelhardt
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Regents of the University of Michigan
InventorsJames M. Wilson, John Engelhardt
Estimating the term…
The present invention comprises an improved adenovirus vector and methods for making and using such vectors. The adenovirus vectors of the present invention retain at least a portion of the adenoviral E3 region, carry a deletion of at least a portion of the adenoviral E1 region. Vectors of the present invention preferably also include an additional deletion to accommodate a transgene and/or other mutations which result in reduced expression or over-expression of adenoviral protein and/or reduced viral replication. The vectors of the present invention further include a transgene operatively-linked thereto. By reducing or eliminating viral replication and viral protein expression, the immune response of the infected host to the virus and viral protein is decreased and persistence of transgene expression can be increased. The adenovirus vectors of the present invention are thus particularly useful in gene transfer and therapy.
An adenoviral vector which comprises an E 2 region having a temperature sensitive mutation and a deletion of the E1 region.
A method of treatment of a defect in a gene in a target cell comprising the step of transferring into the cell a therapeutically effective amount of an adenoviral vector having the gene for cystic fibrosis transmembrane regulator operatively linked thereto, wherein the adenoviral vector comprises an E2 region comprising a temperature sensitive mutation and a deletion of the E1 region, wherein said gene is expressed inside the target cell.
Dependencies are inferred from the claim text.